Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yan-Fa Yu"'
Autor:
Xu-Nian Wu, Ya-Dan Huang, Jin-Xuan Li, Yan-Fa Yu, Zhou Qian, Chen Zhang, Yinuo Wu, Hai-Bin Luo
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 8, Iss 4, Pp 615-628 (2018)
The pathological processes of Alzheimer's disease and type 2 diabetes mellitus have been demonstrated to be linked together. Both PDE9 inhibitors and PPARγ agonists such as rosiglitazone exhibited remarkable preclinical and clinical treatment effect
Externí odkaz:
https://doaj.org/article/b596df79fd294ffebeb44be0ef6b0284
Autor:
Yan-Fa Yu, Chen Zhang, Yi-You Huang, Sirui Zhang, Qian Zhou, Xiangmin Li, Zengwei Lai, Zhe Li, Yuqi Gao, Yinuo Wu, Lei Guo, Deyan Wu, Hai-Bin Luo
Publikováno v:
ACS chemical neuroscience. 11(7)
Phosphodiesterase 10 (PDE10) inhibitors have received much attention as promising therapeutic agents for central nervous system (CNS) disorders such as schizophrenia and Huntington's disease. Recently, a hit compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e866fbdb7e65b4b87384a427b51147
https://pubmed.ncbi.nlm.nih.gov/32105440
https://pubmed.ncbi.nlm.nih.gov/32105440
Autor:
Yinuo Wu, Zhou Qian, Hai-Bin Luo, Chen Zhang, Ya-Dan Huang, Yan-Fa Yu, Jin-Xuan Li, Xu-Nian Wu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 8, Iss 4, Pp 615-628 (2018)
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B
The pathological processes of Alzheimer's disease and type 2 diabetes mellitus have been demonstrated to be linked together. Both PDE9 inhibitors and PPARγ agonists such as rosiglitazone exhibited remarkable preclinical and clinical treatment effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0b220109ca7a24fa44d354b61c5ffe5
https://doi.org/10.1016/j.apsb.2017.12.007
https://doi.org/10.1016/j.apsb.2017.12.007
Publikováno v:
ACS Chemical Neuroscience. 8:2522-2534
Discovery of multitarget-directed ligands (MTDLs), targeting different factors simultaneously to control the complicated pathogenesis of Alzheimer’s disease (AD), has become an important research area in recent years. Both phosphodiesterase 9A (PDE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84590eb5ebb2f63b5f7d901c1ed7ae7d
https://doi.org/10.1021/acschemneuro.7b00268
https://doi.org/10.1021/acschemneuro.7b00268
Autor:
Deyan Wu, Yinuo Wu, Zengwei Lai, Hai-Bin Luo, Yiping Chen, Ya-Dan Huang, Xiaolei Guo, Haiju Geng, Chen Zhang, Yan-Fa Yu, Tianhua Zhang, Chen Jianwen
Publikováno v:
Journal of Medicinal Chemistry. 60:6622-6637
Phosphodiesterase 5 (PDE5) inhibitors have been used as clinical agents to treat erectile dysfunction and pulmonary arterial hypertension (PAH). Herein, we detail the discovery of a novel series of chromeno[2,3-c]pyrrol-9(2H)-one derivatives as selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3eae8ded1bcba2f98ac70ad4456328
https://doi.org/10.1021/acs.jmedchem.7b00523
https://doi.org/10.1021/acs.jmedchem.7b00523
Autor:
Yinuo Wu, Qian Zhou, Yan-Fa Yu, Chen Jianwen, Yi-Jing Tian, Zhe Li, Pei Zhang, Yiping Chen, Yu Wang, Yan Chen, Haiju Geng, Chen Zhang, Hai-Bin Luo, Tianhua Zhang
Publikováno v:
Journal of medicinal chemistry. 62(8)
To identify phosphodiesterase-9 (PDE9) as a novel target for the treatment of vascular dementia (VaD), a series of pyrazolopyrimidinone analogues were discovered based on a hit 1. Hit-to-lead optimization resulted in a potent inhibitor 2 with excelle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf84841062fddfdf5e0323b643d122d6
https://pubmed.ncbi.nlm.nih.gov/30916555
https://pubmed.ncbi.nlm.nih.gov/30916555